CIVILICA We Respect the Science
Publisher of Iranian Journals and Conference Proceedings

Evaluation of Gemcitabine pharmacogenetics effect among the patients affected by pancreatic cancer

Credit to Download: 0 | Page Numbers 1 | Abstract Views: 110
Year: 2016
COI code: IPMCMED01_099
Paper Language: English

How to Download This Paper

For Downloading the Fulltext of CIVILICA papers please visit the orginal Persian Section of website.

Authors Evaluation of Gemcitabine pharmacogenetics effect among the patients affected by pancreatic cancer

  Sahar Hasani - Pharmaceutical sciences branch
  Saeid Morovvati - Molecular Biology Research Center, Baqiyatallah University of Medical Sciences


Gemcitabine is an analog of deoxycytidine with the anticancer effect that is prescribed as a cure for different cancers among Pancreatic cancer that is one of the most aggressive and deadly malignancy cancer. Furthermore, this drug is profitable it can be as well as so toxic. Different genotype variations that are resulted by the polymorphisms of the genes coding the proteins contributing to the enzymatic pathways can affect the expression and function of the proteins that cause various responses in front of the Gemcitabine. One of these proteins is cytidine deaminase (CDA) that its gene is so polymorphic. The clearance of gemcitabine after taken up by the cancer cells driven up by rapid inactivation by CDA to its primary metabolite 2, 2-difluoro- deoxyuridine (dFDU). Each of the different polymorphisms in the CDA gene contributes to its protein activity and can change the gemcitabine clearance process consequently. Considering the toxicity of gemcitabine, its accumulation throughout the body can cause severe poisoning even death among the patient. Pharmacogenetics and personal medicine help us to recognize phenotype- genotype correlation with correct recognition of each of the patient genotype and studying the effect of the polymorphisms on the cytidine deaminase protein activity; according to this correlation can prescribe the anti- cancer drug with appropriate dose and condition for each of the patients. With recent description, these proceedings prevent poisoning and patient death as well as can achieve to the best drug response. Studying the genotype- phenotype correlation between the cytidine deaminase gene and its common polymorphisms according to data are collected from other articles heretofore considered as our aim in this article. We are hopeful of reaching to a desirable conclusion by this collective information about gemcitabine Pharmacogenetics.


Gemcitabine. Polymorphisms. Pharmacogenetics. pancreatic cancer

Perma Link
COI code: IPMCMED01_099

how to cite to this paper:

If you want to refer to this article in your research, you can easily use the following in the resources and references section:
Hasani, Sahar & Saeid Morovvati, 2016, Evaluation of Gemcitabine pharmacogenetics effect among the patients affected by pancreatic cancer, First Personal Medical Congress, تهران, دانشگاه علوم پزشكي ايران - پژوهشكده ملي مهندسي ژنتيك و زيست فناوري ايران، مركز همكاري هاي فناوري و نوآوري هاي رياست جمهوري, the text, wherever referred to or an achievement of this article is mentioned, after mentioning the article, inside the parental, the following specifications are written.
First Time: (Hasani, Sahar & Saeid Morovvati, 2016)
Second and more: (Hasani & Morovvati, 2016)
For a complete overview of how to citation please review the following CIVILICA Guide (Citation)


The University/Research Center Information:
Type: Azad University
Paper No.: 445
in University Ranking and Scientometrics the Iranian universities and research centers are evaluated based on scientific papers.

Research Info Management

Export Citation info of this paper to research management softwares

New Related Papers

Iran Scientific Advertisment Netword

Share this paper


COI is a national code dedicated to all Iranian Conference and Journal Papers. the COI of each paper can be verified online.